Navamedic ASA

Chart & Performance

D1W1MN

P/E

135.79

P/S

0.88

EPS

0.19

Div Yield, %

0.00%

Shrs. gr., 5y

10.11%

Rev. gr., 5y

22.71%

Revenues

512m

+33.98%

Net income

-88.77%

CFO

-87.85%

Dividend

Apr 13, 20101 NOK/sh

Earnings

Jun 04, 2025

Profile

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.

URL

https://navamedic.com/

IPO date

Mar 31, 2006

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title NOK in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title NOK in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	511,997 33.98%	382,135 37.24%	278,439 32.67%
Cost of revenue	370,827	267,075	203,001
Unusual Expense (Income)
NOPBT	141,170	115,060	75,438
NOPBT Margin	27.57%	30.11%	27.09%
Operating Taxes	7,529	13,074	1,740
Tax Rate	5.33%	11.36%	2.31%
NOPAT	133,641	101,986	73,698
Net income	3,304 -88.77%	29,432 4,662.46%	618 -103.75%
Dividends
Dividend yield
Proceeds from repurchase of equity	2,262	1,198
BB yield	-0.35%	-0.20%
Debt
Debt current	70,381	15,709	24,742
Long-term debt	109,704	53,717	50,893
Deferred revenue
Other long-term liabilities	(1)	(1,000)
Net debt	92,900	5,036	5,100
Cash flow
Cash from operating activities	2,179	17,941	(1,300)
CAPEX	(2,198)	(2,251)	(728)
Cash from investing activities	(104,583)	(25,444)	(727)
Cash from financing activities	83,235	10,074	15,931
FCF	138,474	76,284	25,562
Balance
Cash	38,036	64,390	51,698
Long term investments	49,149		18,837
Excess cash	61,585	45,283	56,613
Stockholders' equity	29,815	22,294	(14,245)
Invested Capital	366,317	245,417	222,741
ROIC	43.69%	43.57%	35.93%
ROCE	34.82%	42.98%	36.18%
EV
Common stock shares outstanding	17,613	17,022	16,297
Price	36.70 5.16%	34.90 2.65%	34.00 78.01%
Market cap	646,393 8.81%	594,082 7.22%	554,084 100.60%
EV	739,293	599,118	559,184
EBITDA	153,096	122,302	82,154
EV/EBITDA	4.83	4.90	6.81
Interest	14,337	612	2,501
Interest/NOPBT	10.16%	0.53%	3.32%